Spirogermanium [NSC 192965, Spiro-32] is a germanium derivative which was under development by Unimed Pharmaceuticals. Spirogermanium is not a phase or cell cycle specific drug and inhibits DNA, RNA and protein synthesis, the protein synthesis being the most susceptible to this agent. Activity in malignant lymphoma, ovarian cancer, breast cancer, large bowel cancer, and prostatic cancer was reported in the clinical studies. The drug was under clinical investigation against the wide spectrum of solid tumors and malignant lymphomas. Spirogermanium also exhibits antiarthritic and immunoregulatory activities after p.o. administration to rats. Spirogermanium decreased hindleg inflammatory lesions of adjuvant arthritic rats when administered p.o. before or after the development of the arthritic lesions. However, the therapeutic use of spirogermanium has been discontinued because of its high toxicity and the low response rate.